Core Viewpoint - The collaboration between NVIDIA and Eli Lilly marks a significant investment in AI drug discovery, with both companies committing $1 billion to establish a joint innovation lab in the San Francisco Bay Area, aiming to enhance drug development efficiency through AI and accelerated computing [1][3][8]. Investment and Collaboration - NVIDIA and Eli Lilly will invest approximately $1 billion over the next five years to create a joint innovation lab focused on AI applications in drug discovery [3][7]. - The lab will combine Eli Lilly's expertise in drug development and clinical research with NVIDIA's technology in AI and accelerated computing [7][8]. Market Impact - The announcement has led to a surge in stock prices for several companies in the AI pharmaceutical sector, with notable increases such as 20% for Hongbo Pharmaceutical and over 11% for Weining Health [1][2]. - Eli Lilly's stock has seen a cumulative increase of nearly 34% over the past year, reflecting positive market sentiment towards the collaboration [13]. Industry Trends - The AI pharmaceutical sector is experiencing a pivotal moment, with increased investment and collaboration since 2025, leading to a more diversified industry landscape [16][17]. - By the end of 2025, there were over 350 AI pharmaceutical companies globally, with at least 101 based in China, focusing on critical therapeutic areas [19]. - The global AI drug discovery market was valued between $2.34 billion and $6.93 billion in 2025, with expectations of a compound annual growth rate (CAGR) of 10% to 30% through 2030, and a projected growth rate of 68.3% for the Chinese market [22]. Future Outlook - The partnership is expected to accelerate the transition from traditional drug discovery methods to more engineered designs, leveraging AI technologies [23]. - The AI healthcare sector is anticipated to enter a golden development period, with innovations in medical imaging, intelligent surgical robots, and AI drug development platforms [23]. - Analysts predict that AI will drive new growth in the healthcare industry, particularly in drug development, basic research, diagnosis, and health management [23].

李尧表示："作为全球医药健康行业领跑者，诺华始终秉承'以患者为中心'的核心理念，希望通过创新 和前沿技术创想医药未来。人工智能与生成式生物学不仅是研发工具，更是开启生物医学新纪元的催化 剂。我们也坚信，借助这些前沿技术的创新力量，联合全球特别是中国本土的创新资源，将会为药物研 发带来更多革新，为患者创造更多福祉。" 通过整合海量数据（603138）、结合人工智能的深度学习和高效分析能力，并将其融入药物研发进程， 诺华正逐步成为生成式生物学前沿创新的核心推动者之一。此前，诺华已经与微软建立合作，将机器学 习应用于药物研发——利用人工智能更有效地为患者开发新疗法。 2025年6月24日至26日，世界经济论坛第十六届新领军者年会（夏季达沃斯论坛）在天津举行。本届年 会以"新时代企业家精神"为主题，汇聚来自全球1700余位政商领袖、专家学者共同探讨如何以企业家精 神和创新驱动经济增长与探索产业升级新路径等话题。诺华中国区总裁兼董事总经理李尧受邀参会，并 围绕"'智造'为医药研发带来革新"等话题分享见解。 "智造"刷新医药领域"效率公式" 随着人工智能等前沿技术的不断进展，医药领域也正处于关键转折点，以药物研发为例，传 ...

通过整合海量数据、结合人工智能的深度学习和高效分析能力，并将其融入药物研发进程，诺华正逐步 成为生成式生物学前沿创新的核心推动者之一。此前，诺华已经与微软建立合作，将机器学习应用于药 物研发。 6月24日至26日，世界经济论坛第十六届新领军者年会（夏季达沃斯论坛）在天津举行。本届年会以"新 时代企业家精神"为主题，汇聚来自全球1700余位政商领袖、专家学者共同探讨如何以企业家精神和创 新驱动经济增长与探索产业升级新路径等话题。诺华中国区总裁兼董事总经理李尧受邀参会，并围 绕"智造"为医药研发带来革新等话题分享了见解。 将人工智能融入药品研发 随着前沿技术的不断进展，人工智能和生成式生物学带来的变革，正在重塑"从分子到药物"的旅程。越 来越多的医药企业开始应用人工智能来提升全流程效率。以"创新"为核心竞争力的诺华，也在拥抱这一 变革。 李尧表示，作为全球医药健康行业领跑者，诺华始终秉承'以患者为中心'的核心理念，希望通过创新和 前沿技术创想医药未来。人工智能与生成式生物学不仅是研发工具，更是开启生物医学新纪元的催化 剂。他也坚信，借助这些前沿技术的创新力量，联合全球特别是中国本土的创新资源，将会为药物研发 带来 ...